| Biomarker ID | 811 |
| PMID | 22078333 |
| Year | 2012 |
| Biomarker | %p2PSA |
| Biomarker Basis | Concentration Based (pg/ml) |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in Tumor Stage pt3 |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 2.222 (95% CI: 1.626–3.032); Multivariate: 1.802 (95% CI: 1.264–2.569); |
| Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | pathological stage pt2 Vs pathological stage pt3 |
| Type of Biomarker | Prognostic |
| Cohort | 350 patients with prostate cancer were chosen. 350 patients with prostate cancer were chosen. (n=69) for pt2a,b , (n=39) for pt2c , (n=60) for pt3a, (n=250) for pt3b |
| Senstivity | 90.7 % (95% CI: 83.6–95.5) |
| Specificity | 24.8 % (95% CI:19.5–30.7) |
| AUC | 0.68 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | UniCel DxI800 Immunoassay System analyser (Beckman Coulter Inc., Brea, CA, USA) |
| Clinical | No |
| Remarks | Sensitivity, Specificity calculated at 3 different criterions |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |